The Effects of Hormonal Therapy on Quality of Life in Prostate Cancer

被引：1
作者：
Senoglu, Yusuf [1 ]
Cam, Kamil [2 ]
机构：
[1] Aliaga Devlet Hastanesi, Urol Klinigi, Izmir, Turkey
[2] Marmara Univ, Tip Fak, Urol Anabilim Dali, Istanbul, Turkey
来源：
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY | 2015年 / 14卷 / 04期
关键词：
Prostate cancer; quality of life; hormonal therapy;
D O I：
10.4274/uob.463
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The incidence of prostate cancer is dramatically increasing. Androgen blockade is widely utilized in the management of metastatic and locally advanced prostate cancer. Despite the benefits of this treatment, side effects and shortcoming of quality of life (QoL) constitute the major drawbacks of the hormonal treatment. The proper approach includes precautions in order to provide a lesser impairment in QoL. Therefore, physicians should consider the complications of hormonal treatment and should inform their patients. This review was prepared to point out the QoL changes regarding the hormonal treatment.
引用
收藏
页码：317 / 320
页数：4
相关论文
共 43 条
  • [1] One year follow-up study of the association between chemical castration, sex hormones, beta-amyloid, memory and depression in men
    Almeida, OP
    Waterreus, A
    Spry, N
    Flicker, L
    Martins, RN
    [J]. PSYCHONEUROENDOCRINOLOGY, 2004, 29 (08) : 1071 - 1081
  • [2] EAU guidelines on prostate cancer
    Aus, G
    Abbou, CC
    Bolla, M
    Heidenreich, A
    Schmid, HP
    van Poppel, H
    Wolff, J
    Zattoni, F
    [J]. EUROPEAN UROLOGY, 2005, 48 (04) : 546 - 551
  • [3] Beer TM, 2004, J CLIN ONCOL, V22, p419S
  • [4] Bloomfield DJ, 2004, J CLIN ONCOL, V22, p418S
  • [5] Intermittent Androgen Deprivation for Locally Advanced and Metastatic Prostate Cancer: Results from a Randomised Phase 3 Study of the South European Uroncological Group
    Calais da Silva, Fernando E. C.
    Bono, Aldo V.
    Whelan, Peter
    Brausi, Maurizio
    Marques Queimadelos, Anton
    Portillo Martin, Jose A.
    Kirkali, Ziya
    Calais da Silva, Fernando M. V.
    Robertson, Chris
    [J]. EUROPEAN UROLOGY, 2009, 55 (06) : 1269 - 1277
  • [6] Mortality and institutionalization following hip fracture
    Cree, M
    Soskolne, CL
    Belseck, E
    Hornig, J
    McElhaney, JE
    Brant, R
    Suarez-Almazor, M
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2000, 48 (03) : 283 - 288
  • [7] Physical activity for men receiving androgen deprivation therapy for prostate cancer: benefits from a 16-week intervention
    Culos-Reed, S. Nicole
    Robinson, John W.
    Lau, Harold
    Stephenson, Lynette
    Keats, Melanie
    Norris, Steve
    Kline, Greg
    Faris, Peter
    [J]. SUPPORTIVE CARE IN CANCER, 2010, 18 (05) : 591 - 599
  • [8] Da Silva FC, 2005, AUA ANN M, P21
  • [9] Locally Advanced and Metastatic Prostate Cancer Treated with Intermittent Androgen Monotherapy or Maximal Androgen Blockade: Results from a Randomised Phase 3 Study by the South European Uroncological Group
    da Silva, Fernando Calais
    Calais da Silva, Fernando Manuel
    Goncalves, Frederico
    Santos, Americo
    Kliment, Jan
    Whelan, Peter
    Oliver, Tim
    Antoniou, Nicos
    Pastidis, Spiro
    Queimadelos, Anton Marques
    Robertson, Chris
    [J]. EUROPEAN UROLOGY, 2014, 66 (02) : 232 - 239
  • [10] Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study
    De Angelis, Roberta
    Sant, Milena
    Coleman, Michel P.
    Francisci, Silvia
    Baili, Paolo
    Pierannunzio, Daniela
    Trama, Annalisa
    Visser, Otto
    Brenner, Hermann
    Ardanaz, Eva
    Bielska-Lasota, Magdalena
    Engholm, Gerda
    Nennecke, Alice
    Siesling, Sabine
    Berrino, Franco
    Capocaccia, Riccardo
    [J]. LANCET ONCOLOGY, 2014, 15 (01) : 23 - 34
12345